|
1
|
Benjamin EJ, Muntner P, Alonso A,
Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR,
Cheng S, Das SR, et al: Heart disease and stroke statistics-2019
update: A report from the American Heart Association. Circulation.
139:e56–e528. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu H, Lu K, Zhu J and Wang J: Stem cell
therapy for ischemic heart diseases. Br Med Bull. 121:135–154.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kadota S and Shiba Y: Pluripotent stem
cell-derived cardiomyocyte transplantation for heart disease
treatment. Curr Cardiol Rep. 21:732019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fouts K, Fernandes B, Mal N, Liu J and
Laurita KR: Electrophysiological consequence of skeletal myoblast
transplantation in normal and infarcted canine myocardium. Heart
Rhythm. 3:452–461. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miura K, Okada Y, Aoi T, Okada A,
Takahashi K, Okita K, Nakagawa M, Koyanagi M, Tanabe K, Ohnuki M,
et al: Variation in the safety of induced pluripotent stem cell
lines. Nat Biotechnol. 27:743–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sougawa N, Miyagawa S, Fukushima S,
Kawamura A, Yokoyama J, Ito E, Harada A, Okimoto K, Mochizuki-Oda
N, Saito A and Sawa Y: Immunologic targeting of CD30 eliminates
tumourigenic human pluripotent stem cells, allowing safer clinical
application of hiPSC-based cell therapy. Sci Rep. 8:37262018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gulbins H, Meiser BM, Reichenspurner H and
Reichart B: Cell transplantation-a potential therapy for cardiac
repair in the future? Heart Surg Forum. 5:E28–E34. 2002.PubMed/NCBI
|
|
8
|
Hashimoto H, Olson EN and Bassel-Duby R:
Therapeutic approaches for cardiac regeneration and repair. Nat Rev
Cardiol. 15:585–600. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kang YJ, Jin UH, Chang HW, Son JK, Lee SH,
Son KH, Chang YC, Lee YC and Kim CH: Inhibition of microsomal
triglyceride transfer protein expression and atherogenic risk
factor apolipoprotein B100 secretion by tanshinone IIA in HepG2
cells. Phytother Res. 22:1640–1645. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adams JD, Wang R, Yang J and Lien EJ:
Preclinical and clinical examinations of Salvia miltiorrhiza and
its tanshinones in ischemic conditions. Chin Med. 1:32006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li CZ, Yang SC and Zhao FD: Effects of
tanshinone II-A sulfonate on thrombus formation, platelet and blood
coagulation in rats and mice. Zhongguo Yao Li Xue Bao. 5:39–42.
1984.(In Chinese). PubMed/NCBI
|
|
12
|
Jang SI, Kim HJ, Kim YJ, Jeong SI and You
YO: Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW
264.7 cells: Possible involvement of the NIK-IKK, ERK1/2, p38 and
JNK pathways. Eur J Pharmacol. 542:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu GB, Zhou EX and Qing DX: Tanshinone
II(A) elicited vasodilation in rat coronary arteriole: Roles of
nitric oxide and potassium channels. Eur J Pharmacol. 617:102–107.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wan AK, Leung SW, Zhu DY and Man RY:
Vascular effects of different lipophilic components of ‘Danshen’, a
traditional Chinese medicine, in the isolated porcine coronary
artery. J Nat Prod. 71:1825–1828. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shang Q, Xu H and Huang L: TanshinoneIIA:
A promising natural cardioprotective agent. Evid Based Complement
Alternat Med. 2012:7164592012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu TW, Zeng LH, Fung KP, Wu J, Pang H,
Grey AA, Weisel RD and Wang JY: Effect of sodium tanshinone IIA
sulfonate in the rabbit myocardium and on human cardiomyocytes and
vascular endothelial cells. Biochem Pharmacol. 46:2327–2332. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li K, Song J, Zhao Q, Wang B, Zhang Y,
Wang X, Tang T and Li S: Effective component of Salvia miltiorrhiza
in promoting cardiomyogenic differentiation of human
placenta-derived mesenchymal stem cells. Int J Mol Med. 41:962–968.
2018.PubMed/NCBI
|
|
18
|
Gessert S and Kühl M: The multiple phases
and faces of wnt signaling during cardiac differentiation and
development. Circ Res. 107:186–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parikh A, Wu J, Blanton RM and Tzanakakis
ES: Signaling pathways and gene regulatory networks in
cardiomyocyte differentiation. Tissue Eng Part B Rev. 21:377–392.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pandur P, Läsche M, Eisenberg LM and Kühl
M: Wnt-11 activation of a non-canonical Wnt signalling pathway is
required for cardiogenesis. Nature. 418:636–641. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li D, Sinha T, Ajima R, Seo HS, Yamaguchi
TP and Wang J: Spatial regulation of cell cohesion by Wnt5a during
second heart field progenitor deployment. Dev Biol. 412:18–31.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bisson JA, Mills B, Paul Helt JC, Zwaka TP
and Cohen ED: Wnt5a and Wnt11 inhibit the canonical Wnt pathway and
promote cardiac progenitor development via the Caspase-dependent
degradation of AKT. Dev Biol. 398:80–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cohen ED, Miller MF, Wang Z, Moon RT and
Morrisey EE: Wnt5a and Wnt11 are essential for second heart field
progenitor development. Development. 139:1931–1940. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu AR, Liu L, Chen S, Yang Y, Zhao HJ,
Liu L, Guo FM, Lu XM and Qiu HB: Activation of canonical wnt
pathway promotes differentiation of mouse bone marrow-derived MSCs
into type II alveolar epithelial cells, confers resistance to
oxidative stress, and promotes their migration to injured lung
tissue in vitro. J Cell Physiol. 228:1270–1283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sumi D, Abe K and Himeno S: Arsenite
retards the cardiac differentiation of rat cardiac myoblast H9c2
cells. Biochem Biophys Res Commun. 436:175–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Branco AF, Pereira SP, Gonzalez S, Gusev
O, Rizvanov AA and Oliveira PJ: Gene expression profiling of H9c2
myoblast differentiation towards a cardiac-like phenotype. PLoS
One. 10:e01293032015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shafiq M, Lee SH, Jung Y and Kim SH:
Strategies for recruitment of stem cells to treat myocardial
infarction. Curr Pharm Des. 21:1584–1597. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi M, Li J, Liao L, Chen B, Li B, Chen L,
Jia H and Zhao RC: Regulation of CXCR4 expression in human
mesenchymal stem cells by cytokine treatment: Role in homing
efficiency in NOD/SCID mice. Haematologica. 92:897–904. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Andres RH, Choi R, Pendharkar AV, Gaeta X,
Wang N, Nathan JK, Chua JY, Lee SW, Palmer TD, Steinberg GK and
Guzman R: The CCR2/CCL2 interaction mediates the transendothelial
recruitment of intravascularly delivered neural stem cells to the
ischemic brain. Stroke. 42:2923–2931. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Carotenuto F, Teodori L, Maccari AM,
Delbono L, Orlando G and Di Nardo P: Turning regenerative
technologies into treatment to repair myocardial injuries. J Cell
Mol Med. 24:2704–2716. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen FY, Guo R and Zhang BK: Advances in
cardiovascular effects of tanshinone II(A). Zhongguo Zhong Yao Za
Zhi. 40:1649–1653. 2015.(In Chinese). PubMed/NCBI
|
|
32
|
Xu W, Yang J and Wu LM: Cardioprotective
effects of tanshinone IIA on myocardial ischemia injury in rats.
Pharmazie. 64:332–336. 2009.PubMed/NCBI
|
|
33
|
Zhang Y, Wei L, Sun D, Cao F, Gao H, Zhao
L, Du J, Li Y and Wang H: Tanshinone IIA pretreatment protects
myocardium against ischaemia/reperfusion injury through the
phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic
rats. Diabetes Obes Metab. 12:316–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li K, Li SZ, Zhang YL and Wang XZ: The
effects of dan-shen root on cardiomyogenic differentiation of human
placenta-derived mesenchymal stem cells. Biochem Biophys Res
Commun. 415:147–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hakuno D, Takahashi T, Lammerding J and
Lee RT: Focal adhesion kinase signaling regulates cardiogenesis of
embryonic stem cells. J Biol Chem. 280:39534–39544. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wei H, Juhasz O, Li J, Tarasova YS and
Boheler KR: Embryonic stem cells and cardiomyocyte differentiation:
Phenotypic and molecular analyses. J Cell Mol Med. 9:804–817. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stamos JL and Weis WI: The β-catenin
destruction complex. Cold Spring Harb Perspect Biol. 5:a0078982013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mohammed MK, Shao C, Wang J, Wei Q, Wang
X, Collier Z, Tang S, Liu H, Zhang F, Huang J, et al: Wnt/β-catenin
signaling plays an ever-expanding role in stem cell self-renewal,
tumorigenesis and cancer chemoresistance. Genes Dis. 3:11–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
